Cargando…
Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM
Radiation therapy is a mainstay of cancer treatment, yet the molecular determinants of clinical response are poorly understood. We identified exceptional responders to radiotherapy based on clinical response, and investigated the associated tumor sequencing data in order to identify additional patie...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354661/ https://www.ncbi.nlm.nih.gov/pubmed/28055970 http://dx.doi.org/10.18632/oncotarget.14400 |
_version_ | 1782515356994109440 |
---|---|
author | Ma, Jennifer Setton, Jeremy Morris, Luc Carrillo Albornoz, Pedro Blecua Barker, Christopher Lok, Benjamin H. Sherman, Eric Katabi, Nora Beal, Kathryn Ganly, Ian Powell, Simon N. Lee, Nancy Chan, Timothy A. Riaz, Nadeem |
author_facet | Ma, Jennifer Setton, Jeremy Morris, Luc Carrillo Albornoz, Pedro Blecua Barker, Christopher Lok, Benjamin H. Sherman, Eric Katabi, Nora Beal, Kathryn Ganly, Ian Powell, Simon N. Lee, Nancy Chan, Timothy A. Riaz, Nadeem |
author_sort | Ma, Jennifer |
collection | PubMed |
description | Radiation therapy is a mainstay of cancer treatment, yet the molecular determinants of clinical response are poorly understood. We identified exceptional responders to radiotherapy based on clinical response, and investigated the associated tumor sequencing data in order to identify additional patients with similar mutations. Among head and neck squamous cell cancer patients receiving palliative radiotherapy at our institution, we identified one patient with documented complete metabolic response. Targeted sequencing analysis of the tumor identified a somatic frame-shift mutation in ATM, a gene known to be associated with radio-sensitivity in the germline. To validate the association of somatic ATM mutation with radiotherapy response, we identified eight patients with ATM truncating mutations who received radiotherapy, all of whom demonstrated excellent responses with a median local control period of 4.62 years. Analysis of 22 DNA repair genes in The Cancer Genome Atlas (TCGA) data revealed mutations in 15.9% of 9064 tumors across 24 cancer types, with ATM mutations being the most prevalent. This is the first study to suggest that exceptional responses to radiotherapy may be determined by mutations in DNA repair genes. Sequencing of DNA repair genes merits attention in larger cohorts and may have significant implications for the personalization of radiotherapy. |
format | Online Article Text |
id | pubmed-5354661 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53546612017-04-14 Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM Ma, Jennifer Setton, Jeremy Morris, Luc Carrillo Albornoz, Pedro Blecua Barker, Christopher Lok, Benjamin H. Sherman, Eric Katabi, Nora Beal, Kathryn Ganly, Ian Powell, Simon N. Lee, Nancy Chan, Timothy A. Riaz, Nadeem Oncotarget Research Paper Radiation therapy is a mainstay of cancer treatment, yet the molecular determinants of clinical response are poorly understood. We identified exceptional responders to radiotherapy based on clinical response, and investigated the associated tumor sequencing data in order to identify additional patients with similar mutations. Among head and neck squamous cell cancer patients receiving palliative radiotherapy at our institution, we identified one patient with documented complete metabolic response. Targeted sequencing analysis of the tumor identified a somatic frame-shift mutation in ATM, a gene known to be associated with radio-sensitivity in the germline. To validate the association of somatic ATM mutation with radiotherapy response, we identified eight patients with ATM truncating mutations who received radiotherapy, all of whom demonstrated excellent responses with a median local control period of 4.62 years. Analysis of 22 DNA repair genes in The Cancer Genome Atlas (TCGA) data revealed mutations in 15.9% of 9064 tumors across 24 cancer types, with ATM mutations being the most prevalent. This is the first study to suggest that exceptional responses to radiotherapy may be determined by mutations in DNA repair genes. Sequencing of DNA repair genes merits attention in larger cohorts and may have significant implications for the personalization of radiotherapy. Impact Journals LLC 2016-12-31 /pmc/articles/PMC5354661/ /pubmed/28055970 http://dx.doi.org/10.18632/oncotarget.14400 Text en Copyright: © 2017 Ma et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Ma, Jennifer Setton, Jeremy Morris, Luc Carrillo Albornoz, Pedro Blecua Barker, Christopher Lok, Benjamin H. Sherman, Eric Katabi, Nora Beal, Kathryn Ganly, Ian Powell, Simon N. Lee, Nancy Chan, Timothy A. Riaz, Nadeem Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM |
title | Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM |
title_full | Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM |
title_fullStr | Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM |
title_full_unstemmed | Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM |
title_short | Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM |
title_sort | genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in atm |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354661/ https://www.ncbi.nlm.nih.gov/pubmed/28055970 http://dx.doi.org/10.18632/oncotarget.14400 |
work_keys_str_mv | AT majennifer genomicanalysisofexceptionalresponderstoradiotherapyrevealssomaticmutationsinatm AT settonjeremy genomicanalysisofexceptionalresponderstoradiotherapyrevealssomaticmutationsinatm AT morrisluc genomicanalysisofexceptionalresponderstoradiotherapyrevealssomaticmutationsinatm AT carrilloalbornozpedroblecua genomicanalysisofexceptionalresponderstoradiotherapyrevealssomaticmutationsinatm AT barkerchristopher genomicanalysisofexceptionalresponderstoradiotherapyrevealssomaticmutationsinatm AT lokbenjaminh genomicanalysisofexceptionalresponderstoradiotherapyrevealssomaticmutationsinatm AT shermaneric genomicanalysisofexceptionalresponderstoradiotherapyrevealssomaticmutationsinatm AT katabinora genomicanalysisofexceptionalresponderstoradiotherapyrevealssomaticmutationsinatm AT bealkathryn genomicanalysisofexceptionalresponderstoradiotherapyrevealssomaticmutationsinatm AT ganlyian genomicanalysisofexceptionalresponderstoradiotherapyrevealssomaticmutationsinatm AT powellsimonn genomicanalysisofexceptionalresponderstoradiotherapyrevealssomaticmutationsinatm AT leenancy genomicanalysisofexceptionalresponderstoradiotherapyrevealssomaticmutationsinatm AT chantimothya genomicanalysisofexceptionalresponderstoradiotherapyrevealssomaticmutationsinatm AT riaznadeem genomicanalysisofexceptionalresponderstoradiotherapyrevealssomaticmutationsinatm |